MarketCap
Facebook
X
Telegram
Albireo Pharma DIO Ratio | ALBO
Annual DIO Ratio Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.1 | 26.1 | 26.1 |
Quarterly DIO Ratio Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 391 | 230 | 393 | - | 20.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 393 | 20.8 | 259 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
AbbVie
ABBV
|
91.6 | $ 294.72 | 0.32 % | $ 521 B |  USA |
 |
Axon Enterprise
AXON
|
98.8 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
68.7 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Dynavax Technologies Corporation
DVAX
|
455 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
200 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
3.22 | - | -33.86 % | $ 61.2 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
224 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
161 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
602 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
0.33 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
218 | - | - | $ 121 M | USA |
 |
Eli Lilly and Company
LLY
|
352 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
343 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
149 | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
71.7 | - | -47.76 % | $ 6.27 M | USA |
 |
Moderna
MRNA
|
56.8 | $ 248.62 | -0.88 % | $ 96.7 B | USA |